Home / Market News / $TEVA
benzinga Corporate Catalyst Impact 75/100 ● positive

Teva Pharma And Sanofi Report Duvakitug Maintained Efficacy Through 44 Weeks In Ulcerative Colitis And Crohn's Disease

Oct 20, 2026, 12:02 PM UTC · Primary ticker $TEVA

Teva Pharmaceuticals and Sanofi announced positive long-term extension data for their investigational drug duvakitug, showing sustained efficacy in treating ulcerative colitis and Crohn's disease over 44 weeks. This data reinforces the drug's potential as a significant treatment option for these inflammatory bowel diseases, positively impacting both companies' drug pipelines and future revenue prospects.

Teva Pharmaceuticals and Sanofi reported new positive data from the RELIEVE UCCD phase 2b long-term extension study for duvakitug, an investigational drug for ulcerative colitis (UC) and Crohn's disease (CD). The study demonstrated that duvakitug maintained high rates of clinical remission, response, and endoscopic improvement through 44 weeks, with a safety profile consistent with the induction study. This is significant because it validates the long-term potential of duvakitug as a treatment for these chronic inflammatory bowel diseases, which currently have unmet medical needs. For traders, this represents a positive development for both TEVA and SNY, as it strengthens their respective drug pipelines and could lead to substantial future revenue if the drug progresses through further trials and gains regulatory approval. The short-term implication is increased investor confidence, while the long-term opportunity lies in market share capture within the IBD treatment landscape.

$TEVA positive Positive clinical trial data for key pipeline drug
$SNY positive Positive clinical trial data for key pipeline drug
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.